{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","lowerLimit":"0.08","upperLimit":"0.64","value":"0.29"}]}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"7"}],"units":"Participants"}],"description":"Response rate is the proportion of patients with overall complete (CR) or partial response(PR) among patients with valuable response outcome. Overall response will consider both target and non-target lesions, as well as new lesions.\n\nTarget lesions by CT/MRI: CR: Disappearance of all target lesions. PR: \\>= 30% decrease in the sum of diameters of target lesions. Progressive Disease (PD): \\>= 20% increase in the sum of diameters of target lesions, In addition, the sum must also demonstrate an absolute increase of at least 5 mm or appearance of new lesions. Non-target lesions: CR: Disappearance of all target lesions. Non-CR/Non-PD: Persistence of one or more non-target lesion(s) and/or maintenance of applicable tumor marker level above the normal limits. PD: progression of existing non-target lesions.","dispersionType":"95% Confidence Interval","groups":[{"description":"Participants receive avelumab by IV infusion following pretreatment with H1 blockers and acetaminophen once every 2 weeks.\n\nAvelumab: Avelumab through a vein once every 2 weeks","id":"OG000","title":"Avelumab Monotherapy"}],"paramType":"NUMBER","populationDescription":"Patients with advanced small intestinal adenocarcinoma or ampullary tumors, efficacy-evaluable.","reportingStatus":"POSTED","timeFrame":"Measured every 8 weeks through study completion, an average of 1 year","title":"Overall Response Rate as Measured Using RECIST 1.1","type":"PRIMARY","unitOfMeasure":"proportion of participants"}